Lung Squamous Cell Carcinoma Clinical Trial
Official title:
An Open-label, Single-arm Clinical Study to Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation
This is an open-label, sing-arm, single site, phase IV clinical study. The main objective is to evaluate the efficacy of afatinib in LSQC patients with EGFR sensitive mutation, and to explore the clinical factors which might be predictive for the effectiveness in LSQC.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | August 31, 2021 |
Est. primary completion date | April 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Selected patients must meet all of the following standards: 1. The patient's or his/her legal representative's has signed and dated written informed consent before any specific study procedure. 2. The patient is above 18 years old. 3. Locally advanced (IIIB) or metastatic (stage IV) immunohistochemistry (IHC)-verified Lung squamous cell carcinoma (LSQC) with EGFR sensitive mutation patients, whom previously untreated or received platinum-based doublet chemotherapy as first-line treatment with subsequent disease progression, and had to be eligible for second-line treatment. 4. The patient has NOT previously received EGFR-TKI treatment. 5. ECOG Performance Status Score is 0~2. 6. The patient has sufficient bone marrow and organ function proved by baseline complete plasma count, plasma biochemistry and urinary biochemistry tests. 7. Female patients of childbearing age must use adequate contraceptives, and breastfeeding is not allowed. 8. Male patients must voluntarily to use contraceptives. Exclusion criteria - Selected patients can not meet any one of the following standards: 1. The patient has received EGFR-TKI treatment. 2. The patient has any severe or uncontrolled systemic signs of illness, including uncontrolled hypertension, active easy-bleeding constitution, active infection, or significantly impaired function of bone marrow or organs, which researchers believe can significantly change the patient's risk/benefit balance. 3. The patient has symptomatic central nervous system (CNS) metastases. 4. The patient has the history of interstitial pneumonia, or radiation pneumonia which needs steroid treatment. 5. The patient still has unrecovered toxic reaction with = grade 3 (CTCAE5.0) caused by previously received treatment. |
Country | Name | City | State |
---|---|---|---|
China | Shanghai Chest Hospital | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai Chest Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival (PFS) | PFS refers to the time from initial prescription of afatinib to the time of disease progression or death recorded in CRF in this study, no matter whether the patient withdraw from the treatment before disease progression or receive other anti-cancer treatment or not. For the patient without progression or death at the time of analysis, the latest assessment date will be used as interpolation (censoring). (Or, if there's no tumor assessment after baseline visit, baseline visit date will be used | Up to 12 months | |
Secondary | Objective response rate (ORR) | ORR refers to the incidence of complete remission (CR) or partial remission (PR) (determined according to RECIST1.1 standards) | Up to 12 months | |
Secondary | Overall survival (OS) | OS refers to the time from the patient entering into the group to the time of death. When it comes to the analysis of patients with unknown survival status, the last date when learning of the patient's survival will be used as interpolation (censoring) | Up to 12 months | |
Secondary | Rate of SAEs, dose change-induced AEs, and AEs of particular concerns. | Serious adverse events [SAEs], dose change-induced AEs, and AEs of particular concerns. | Up to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04267913 -
Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)
|
Phase 2 | |
Not yet recruiting |
NCT03725423 -
Apatinib for Advanced Lung Squmamous Carcinoma
|
Phase 4 | |
Recruiting |
NCT06255197 -
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
|
||
Active, not recruiting |
NCT04152018 -
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
|
Phase 1 | |
Recruiting |
NCT05778253 -
The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC
|
||
Recruiting |
NCT02876978 -
Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma
|
Phase 1 | |
Completed |
NCT01807546 -
Oral Rigosertib for Squamous Cell Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT01386385 -
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00334815 -
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
|
Phase 2 | |
Recruiting |
NCT05782764 -
A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom
|
Phase 4 | |
Recruiting |
NCT05010330 -
Identify Prognostic Biomarkers of Lung Cancer
|
||
Recruiting |
NCT06436040 -
Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma
|
||
Recruiting |
NCT05024266 -
Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT04802876 -
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors
|
Phase 2 |